In the use of low-level intravenous insulin infusion for treating diabetic hyperglycaemia and ketoacidosis adsorption of insulin to containers or plastic infusion apparatus results in significant losses of 60-80% of insulin in dilute physiological saline solution (40 U/1). It is therefore necessary to add protein to the carrier solution to minimize losses and maintain a constant delivery rate. Recovery studies showed that 3-5% w/v polygeline solution (polymer of degraded gelatin) was a suitable medium for this purpose, offering some advantages over human serum albumin. A minimum concentration of 0 5% polygeline was required to ensure adequate delivery of insulin to the patient.
Methods
We added 20 units of crystalline porcine insulin (Novo Actrapid, concentration 40 kU/1) to the following standard 500-ml containers: (a) a plastic container holding polygeline 3-5%; (b) a glass container holding polygeline 3 5%; (c) a glass container holding saline 0-9% and H.S.A. 2% (Commonwealth Serum Laboratories, Melbourne); (d) a glass container holding saline 0-9%; and (e) a plastic container holding saline 0-9%.
The solutions were mixed by agitating the containers, and 15 minutes after the addition of insulin aliquots were taken for assay. The containers were then connected to controlled paediatric drip sets and each adjusted to a flow rate of about 1 ml/min. The effluent was collected-for insulin assay after two and a half, five, and eight hours. The experiment was performed at 22'C. Immediately after collection samples were frozen in plastic tubes and stored at -20°C. Later they were thawed, diluted to 1/700, and assayed for immunoreactive insulin using a commercial radioimmunoassay kit (Sorin, Italy). The quoted oontent of the original insulin phial was also checked by radioimmunoassay. In pilot studies insulin standard curves set up in buffer and in the above carrier solutions diluted to 1/700 were equivalent.
In a further experiment to investigate the relation of insulin recovery to concentration of polygeline in the carrier solution 500-ml glass infusion containers were set up with saline as a diluent to produce a range of concentrations of polygeline from 0 to 3-5%. After addition of insulin as in the first experiment the solutions were left standing at 22°C with frequent gentle agitation, and aliquots were taken for insulin assay after 15 minutes and two hours.
Insulin recoveries were expressed as a ratio of the measured to expected insulin concentration. Statistical comparisons were performed by a Wilcoxon test.
Results
Recovery of insulin from the five combinations of solutions and containers tested are shown in fig. 1 . Each point is the mean of duplicate determinations. The overall within-assay precision in determination of insulin recovery was estimated to be 4-7% from Snedecor's approximation of duplicate differences.9 There was no discernible downward trend in insulin recovery over the eight-hour period in any case. For statistical comparison a mean recovery of insulin (+ S.D.) over the time studied was calculated for each case. The recovery of insulin from dilute solution is likely to be influenced by both the surface area in contact with the infusion solution and the concentration of insulin in the carrier solution. 6 These methodological differences make it somewhat difficult to compare our results with those of others. Nevertheless, our results for recovery from saline and saline plus H.S.A. solutions generally agree with the only other report6 which assessed insulin recovery by radioimmunoassay, though the initial recovery of insulin in our studies from saline plus H.S.A. was lower. Recovery assessed by radioimmunoassay is lower than that assessed by recovery of radioactivity after the addition of 1251-insulin to the infusion bottle.6 This may perhaps be due to non-specific binding of insulin to macromolecules in the carrier solution. It has been shown8 that concentrated gelatin solution (1-4%) increases non-specific binding of labelled insulin.
From our results we conclude that loss of insulin from dilute solutions in contact with standard infusion apparatus can be substantially reduced (to less than 20%) using a commercial 3-5% polygeline solution, that insulin losses from this solution are no greater than losses from H.S.A. and saline solutions, and that loss of activity of insulin in this medium at room temperature does not increase with time within eight hours. Furthermore, the polygeline solution seems to be equally effective down to concentrations of 0-5%.
Methods of treatment of diabetic ketoacidosis by low-dose constant intravenous insulin infusion vary in the degree of dilution of insulin in the infusion solution.1-3 Our studies simulated conditions of insulin delivery in which insulin is diluted to a concentration of 40 U/1.2 When insulin is present in relatively high concentrations in an infusion syringe (1) (2) (3) (4) 
SHORT REPORTS Deanol in Tardive Dyskinesia
Tardive dyskinesia is a common and sometimes disabling complication of prolonged treatment with neuroleptic drugs, particularly the phenothiazines and butyrophenones (members of this group include haloperidol and triperidol).1 It has caused much concern recently mainly because of its persistent nature, but despite much effort to combat this condition no proper treatment is available.2 Though its exact pathophysiology is not clear, the most widely held view is that tardive dyskinesia is due to a hypersensitivity of striatal receptors to dopamine caused by the blocking action on these receptors of phenothiazines and butyrophenones. If this were so one would expect that a drug which would increase the acetylcholine content in the striatum would be effective in controlling tardive dyskinesia, as acetylcholine has antagonistic effects to dopamine at that site. Deanol3 has just such properties and has been shown to be effective in the treatment of tardive dyskinesia.4 It has been used for many years, mainly for the learning and behaviour problems of children and has proved to be remarkably safe. We treated four patients with tardive dyskinesia with deanol not only to confirm earlier reports4 5 but also to determine whether the drug was as effective when given while the offending drug was still being used.
Case Reports Case 1.-This 46-year-old woman had been treated for schizophrenia for several years with high doses of thioridazine together with benztropine. She had had a predominantly buccolingual masticatory dyskinesia for some years, which had become severe and disabling for several weeks despite the withdrawal of benztropine. Deanol was started and gradually increased over two weeks to 800 mg/day in divided doses. After one week at this dose the dyskinesia completely disappeared.
Case 2.-This was a 62-year-old woman with presenile dementia, most probably due to Alzheimer's disease, who had received trifluoperazine, followed by thioridazine, in moderate doses for about 10 years. She had concurrently received benztropine till about a year before and had received promethazine some years previously. For a few years she had had buccolingualmasticatory dyskinesia. Deanol was started and gradually increased over one week to 800 mg/day. It completely abolished the dyskinesia on reaching that dose. 
